AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21875244 — intervention group
Group type: COMPARATOR
Intervention: Categorical decision advice alone
Number of subjects: 0
Study 21875244 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of decision advice with uncertainty estimates
Number of subjects: 0
Study 20391212 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct measures of comparative risk perceptions
Number of subjects: 0
Study 20391212 — intervention group
Group type: COMPARATOR
Intervention: Indirect measures of comparative risk perceptions
Number of subjects: 0
Study 18359604 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative intervention (n=79): Patients wrote a story about how cancer affected their lives for at least 20 minutes once a week for three weeks.
Number of subjects: 234
Study 18359604 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire intervention (n=77): Patients filled out the McGill Pain Questionnaire.
Number of subjects: 234
Study 18359604 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=78): Patients received usual customary care during weekly medical visits.
Number of subjects: 234
Study 16483052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal Misoprostol
Number of subjects: 20
Study 16483052 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical Foley catheter
Number of subjects: 20
Study 12088958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lafutidine 20 mg
Number of subjects: 0
Study 12088958 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study 12088958 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole
Number of subjects: 0
Study 10585309 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients (n = 71)
Number of subjects: 256
Study 10585309 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients (n = 185)
Number of subjects: 256
Study 9592319 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate (MA) 160 mg/day orally for two weeks
Number of subjects: 31
Study 9592319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 1910254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering diet
Number of subjects: 272
Study 1910254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 272
Study 6628224 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorophyllin 100 mg/d for two weeks
Number of subjects: 20
Study 6628224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31693787 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1226
Study 31343402 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (200 mg once or twice a day) for 1 year
Number of subjects: 1578
Study 31343402 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 1578
Study 31343402 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline
Number of subjects: 1578
Study 31343402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1578
Study 29520729 — intervention group
Group type: COMPARATOR
Intervention: Velpatasvir 100 mg single dose
Number of subjects: 43
Study 29520729 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir ± ribavirin for 12 weeks or sofosbuvir/velpatasvir for 24 weeks
Number of subjects: 43
Study 25687131 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone SMS for diabetes communication
Number of subjects: 515
Study 24215017 — intervention group
Group type: EXPERIMENTAL
Intervention: Single time-point FGF23 measurement
Number of subjects: 439
Study 24215017 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-averaged FGF23 measurement
Number of subjects: 439
Study 24215017 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in FGF23
Number of subjects: 439
Study 21292732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bis‐GMA/TEGDMA resin with 20% silane‐coated silica
Number of subjects: 160
Study 21292732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bis‐GMA/TEGDMA resin with 60% silane‐coated silica
Number of subjects: 160
Study 21292732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bis‐GMA/TEGDMA resin with 80% silane‐coated silica
Number of subjects: 160
Study 21292732 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT (control group)
Number of subjects: 160
Study 19172226 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency exerciser (HFE) - continued exercise training at least 30 min at least 3 days/week
Number of subjects: 45
Study 19172226 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency exerciser (LFE) - exercise training at least 30 min twice per week or less
Number of subjects: 45
Study 19172226 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 17301265 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain n-3 fatty acids (highest vs lowest quartile)
Number of subjects: 460
Study 17301265 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain n-3 fatty acids (quartiles) among men not on aspirin
Number of subjects: 460
Study 17301265 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain n-6 fatty acids (highest vs lowest quartile)
Number of subjects: 460
Study 17301265 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (randomized assignment)
Number of subjects: 460
Study 15673098 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CrS)
Number of subjects: 7
Study 15673098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 12214460 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Number of subjects: 0
Study 12214460 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin
Number of subjects: 0
Study 9823662 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 30
Study 9823662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7650231 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg bid
Number of subjects: 18
Study 7650231 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine 50 mg tid
Number of subjects: 18
Study 3353045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 25
Study 3353045 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 25
Study 30817999 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-peptide vaccine nelipepimut-S + GM-CSF with trastuzumab
Number of subjects: 150
Study 30817999 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab + GM-CSF
Number of subjects: 150
Study 28938963 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic human mesenchymal stem cell injection
Number of subjects: 20
Study 28938963 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical care (no injection)
Number of subjects: 20
Study 25409551 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG‐Valsalva maneuver
Number of subjects: 31
Study 25409551 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver alone
Number of subjects: 31
Study 24179108 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple hand hygiene plus antiseptic hand hygiene (water and glycerin soap for 1 minute followed by 70% ethyl alcohol gel)
Number of subjects: 22
Study 24179108 — intervention group
Group type: COMPARATOR
Intervention: Antiseptic hand hygiene (70% ethyl alcohol gel until fully dry)
Number of subjects: 22
Study 24179108 — intervention group
Group type: COMPARATOR
Intervention: Regular hygiene group (control)
Number of subjects: 22
Study 24179108 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel-only group (intervention)
Number of subjects: 22
Study 16388809 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin for 3 months
Number of subjects: 141
Study 16388809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 14717485 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon (sodium hyaluronate) 0.05 ml injected into anterior chamber; n = 20
Number of subjects: 38
Study 14717485 — intervention group
Group type: COMPARATOR
Intervention: Control (balanced salt solution) 0.05 ml injected into anterior chamber; n = 18
Number of subjects: 38
Study 10390129 — intervention group
Group type: EXPERIMENTAL
Intervention: Etofibrate treatment for 6 weeks
Number of subjects: 21
Study 10390129 — intervention group
Group type: COMPARATOR
Intervention: Standardized fatty meal
Number of subjects: 21
Study 8888597 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression (instructions not to think about the film)
Number of subjects: 2
Study 8888597 — intervention group
Group type: COMPARATOR
Intervention: Thinking about the film (instructions to think about the film)
Number of subjects: 2
Study 8888597 — intervention group
Group type: COMPARATOR
Intervention: No instructions (control group)
Number of subjects: 2
Study 1381626 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (230 micrograms/m2 daily subcutaneous)
Number of subjects: 80
Study 1381626 — intervention group
Group type: COMPARATOR
Intervention: Control (VAPEC-B chemotherapy alone)
Number of subjects: 80
Study 6151371 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 74
Study 6151371 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 74
Study 6151371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 74
Study 31022142 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Z‐plasty palatoplasty
Number of subjects: 40
Study 31022142 — intervention group
Group type: COMPARATOR
Intervention: Double opposing Z‐plasty and Sommerlad palatoplasty
Number of subjects: 40
Study 27797930 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 27
Study 27797930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 25755211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelarabine (n=47)
Number of subjects: 94
Study 25755211 — intervention group
Group type: COMPARATOR
Intervention: Non-nelarabine arm (n=47)
Number of subjects: 94
Study 22554076 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress group (political violence video clip)
Number of subjects: 107
Study 22554076 — intervention group
Group type: COMPARATOR
Intervention: No-stress group (nature video clip)
Number of subjects: 107
Study 22254708 — intervention group
Group type: EXPERIMENTAL
Intervention: Real exposure to 12.5 μT magnetic fields at 60 Hz for 30 minutes
Number of subjects: 31
Study 22254708 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 31
Study 19486651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio group (n=66) - cardiovascular exercises for 45-60 min at 60-70% maximal oxygen uptake, 3 sessions per week
Number of subjects: 127
Study 19486651 — intervention group
Group type: COMPARATOR
Intervention: Flex group (n=61) - non-cardiovascular flexibility and balance exercises, 2 sessions per week
Number of subjects: 127
Study 17234805 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute resistance exercise (RE)
Number of subjects: 8
Study 15297101 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified casein
Number of subjects: 8
Study 15297101 — intervention group
Group type: COMPARATOR
Intervention: Dephosphorylated casein
Number of subjects: 8
Study 11314884 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg amoxicillin plus 250 mg metronidazole every 8 hours for 7 days
Number of subjects: 49
Study 11314884 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets every 8 hours for 7 days
Number of subjects: 49
Study 11314884 — intervention group
Group type: COMPARATOR
Intervention: Test group (antibiotics) vs. Placebo group
Number of subjects: 49
Study 11314884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pg-pos subgroup (test)
Number of subjects: 49
Study 11314884 — intervention group
Group type: COMPARATOR
Intervention: Pg-pos subgroup (placebo)
Number of subjects: 49
Study 11314884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pg-neg subgroup (test)
Number of subjects: 49
Study 11314884 — intervention group
Group type: COMPARATOR
Intervention: Pg-neg subgroup (placebo)
Number of subjects: 49
Study 9041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum cardiac troponin T (cTnT) concentrations greater than 0.20 micrograms/L at baseline
Number of subjects: 16
Study 9041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum creatine kinase MB (CK‐MB) greater than 5.0 micrograms/L at baseline
Number of subjects: 16
Study 9041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum cardiac troponin I (cTnI) greater than 0.8 micrograms/L at baseline
Number of subjects: 16
Study 9041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac event rate over 1 year
Number of subjects: 16
Study 9041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased ELISA cTnT levels at 1 year
Number of subjects: 16
Study 9041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased CK‐MB levels at 1 year
Number of subjects: 16
Study 9041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated cTnI levels at 1 year
Number of subjects: 16
Study 9041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Reanalysis of ELISA cTnT values with a newly formulated Enzymun cTnT assay
Number of subjects: 16
Study 7946229 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural training programme administered by nurses combining life skills training, active encouragement, and a token economy
Number of subjects: 52
Study 7946229 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training or reinforcement)
Number of subjects: 52
Study 2452570 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen peroxide at 0 ppm
Number of subjects: 8
Study 2452570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 25 ppm
Number of subjects: 8
Study 2452570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 50 ppm
Number of subjects: 8
Study 2452570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 100 ppm
Number of subjects: 8
Study 2452570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 200 ppm
Number of subjects: 8
Study 2452570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 400 ppm
Number of subjects: 8
Study 2452570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 800 ppm
Number of subjects: 8
Study 29058130 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Thermometer (DT)
Number of subjects: 165
Study 29058130 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DT and HADS scores
Number of subjects: 165
Study 28093573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advices and physical activity assessed by pedometer (PA+D)
Number of subjects: 425
Study 28093573 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity assessed by pedometer (PA)
Number of subjects: 425
Study 28093573 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 425
Study 28093573 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliant women (less than 11,000 steps per day)
Number of subjects: 425
Study 28093573 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate intake
Number of subjects: 425
Study 28093573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention and control groups
Number of subjects: 425
Study 26316264 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care transplant education provided by the dialysis center
Number of subjects: 540
Study 26316264 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-guided ETH (ETH-PG)
Number of subjects: 540
Study 26316264 — intervention group
Group type: EXPERIMENTAL
Intervention: Health educator-guided ETH (ETH-EG)
Number of subjects: 540
Study 22448901 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal TDCS (2mA for 20min, 5 daily sessions)
Number of subjects: 50
Study 22448901 — intervention group
Group type: COMPARATOR
Intervention: Sham TDCS
Number of subjects: 50
Study 21354343 — intervention group
Group type: COMPARATOR
Intervention: Excision with primary repair
Number of subjects: 100
Study 21354343 — intervention group
Group type: EXPERIMENTAL
Intervention: Limberg flap
Number of subjects: 100
Study 18079286 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI, 20 mg/day)
Number of subjects: 100
Study 18079286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18079286 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg) as rescue medication
Number of subjects: 100
Study 17313004 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Zusanli (ST 36) and Xuanzhong (GB 39)
Number of subjects: 160
Study 17313004 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment for ischemic stroke (Control group)
Number of subjects: 160
Study 12750656 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-Hour Schedule (24HS) questionnaire and assessment by trained examiners
Number of subjects: 40
Study 12750656 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of back posture (flexed vs. lordotic)
Number of subjects: 40
Study 10972330 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic dendritic cells pulsed with HIV MN gp160 protein or peptides from HLA-A2 restricted epitopes of env, gag, and pol proteins, infused every month for 6-9 months.
Number of subjects: 5
Study 10972330 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic dendritic cells infusion
Number of subjects: 5
Study 9168216 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol and beta-cyclodextrin piroxicam (BCPT)
Number of subjects: 48
Study 9168216 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 48
Study 9168216 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-cyclodextrin piroxicam (BCP)
Number of subjects: 48
Study 9168216 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo tablet and saline infusion)
Number of subjects: 48
Study 1556523 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g Na2EDTA
Number of subjects: 153
Study 1556523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 3893599 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot neuroleptics
Number of subjects: 73
Study 31087451 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ANAIS (intervention group)
Number of subjects: 80
Study 31087451 — intervention group
Group type: COMPARATOR
Intervention: Delayed ANAIS (control group)
Number of subjects: 80
Study 30197148 — intervention group
Group type: EXPERIMENTAL
Intervention: Kleb‐SRP vaccine administered before calving
Number of subjects: 569
Study 30197148 — intervention group
Group type: EXPERIMENTAL
Intervention: Kleb‐SRP vaccine administered after calving
Number of subjects: 569
Study 30197148 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 569
Study 26865592 — intervention group
Group type: COMPARATOR
Intervention: Sf2aWC vaccine (formalin‐inactivated whole‐cell Shigella flexneri 2a), given orally in three doses (2.6 ± 0.8 × 10(8), × 10(9), × 10(10), and × 10(11)vaccine particles/ml)
Number of subjects: 82
Study 26865592 — intervention group
Group type: COMPARATOR
Intervention: Sf2aWC vaccine
Number of subjects: 82
Study 24488983 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropic therapy (dobutamine 43%, dopamine 24%, milrinone 17%, combination 16%)
Number of subjects: 126564
Study 24488983 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher risk-standardized inotrope use
Number of subjects: 126564
Study 22747904 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (IG)
Number of subjects: 192
Study 22747904 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 192
Study 21319614 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance cue provided to the kicker
Number of subjects: 32
Study 21319614 — intervention group
Group type: COMPARATOR
Intervention: No advance cue (Control group)
Number of subjects: 32
Study 17441415 — intervention group
Group type: EXPERIMENTAL
Intervention: GliSODin (vegetal SOD with gliadin)
Number of subjects: 76
Study 17441415 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 76
Study 16255189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of Zinacef
Number of subjects: 0
Study 12523682 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (n = 10)
Number of subjects: 250
Study 12523682 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (n = 10)
Number of subjects: 250
Study 10334653 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt enriched with Lactobacillus acidophilus L‐1
Number of subjects: 78
Study 10334653 — intervention group
Group type: COMPARATOR
Intervention: Control yoghurt
Number of subjects: 78
Study 8532943 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil
Number of subjects: 20
Study 8532943 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 8532943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1904120 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance group received six weekly instillations of 80 mg of BCG and four additional instillations every three months.
Number of subjects: 42
Study 1904120 — intervention group
Group type: COMPARATOR
Intervention: Non-maintenance group received six weekly instillations of 80 mg of BCG.
Number of subjects: 42
Study 1904120 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pT1b tumor in maintenance group.
Number of subjects: 42
Study 31822157 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylphthalide injection
Number of subjects: 98
Study 31822157 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 98
Study 30477629 — intervention group
Group type: EXPERIMENTAL
Intervention: PND 0.5 group
Number of subjects: 24
Study 30477629 — intervention group
Group type: EXPERIMENTAL
Intervention: PND 7 group
Number of subjects: 24
Study 27788931 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stents
Number of subjects: 283
Study 27788931 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 283